Related Experiment Video
Updated: Mar 31, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
FV-ARG-506-GLN-Mutation-associated resistance to activated protein C in ischemic stroke
T Tatlisumak1, M Syrjälä2, P Lindsberg3
1Department of Neurology, Helsinki University Central Hospital, Haart-maninkatu, Helsinki, Finland.
Abstract:
A recently described coagulation disorder [FV-Arg-506-Gln-mutation-associated resistance to activated protein C (APC-resistance)] leads to a five- to tenfold increased risk for venous thromboembolism. The aim of the study was to determine if this disorder also predisposes to ischemic stroke. Ninety-nine consecutive patients with ischemic stroke of noncardiac origin were screened for APC-resistance and tested for the FV-Arg-506-Gln mutation. The FV-Arg-506-Gln mutation was found in 5 of the 99 stroke patients and in 6% of a pool of blood donors. FV-Arg-506-Gln mutation is not a major cause of ischemic stroke. However, a minor predisposing effect cannot be excluded. Further studies with larger stroke populations and subpopulations are indicated to determine the exact impact of this condition on ischemic stroke.
More Related Videos
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
06:59The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Clot Retraction and Fibrinolysis
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...